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The designer of a clinical trial needs to make many assumptions about real-life practice based on prior
knowledge. Simulation allows us to learn from experience by using the information obtained from a trial
to improve the original estimators of population parameters. We propose using data from a previous trial
to formulate assumptions that can be used to simulate trials and thus improve the design of new trials.
To demonstrate our method, we used data from a real clinical trial which had been designed to evaluate
cholesterol level changes as a surrogate marker for lipodystrophy in HIV patients. We were able to iden-
tify the optimal design that would have minimised the cost of a trial subject to a statistical power con-
straint which could then be used to design a new trial. In particular, we focused on three factors: the
distribution of cholesterol levels in HIV patients, trial recruitment rates and trial dropout rates. We were
able to verify our hypothesis that the total cost resulting from carrying out a clinical trial can be mini-
mised by applying simulation models as an alternative to conventional approaches.
In our ﬁndings the simulationmodel proved to be very intuitive and a useful method for testing the per-
formance of investigators’ assumptions and generating an optimal clinical trial design before being put into
practice in the realworld. In addition, we concluded that simulationmodels provide amore accurate deter-
mination of power than conventional approaches, thus minimising the total cost of clinical trials.
 2008 Elsevier Inc. All rights reserved.1. Introduction
A randomised clinical trial can take a long time and be expen-
sive, so optimised designs offer advantages in terms of alternative
outcomes or surrogate endpoints, which in turn could reduce the
cost of the trial while still maintaining high statistical power [1–4].
The design of a clinical trial depends, among other things, on
prior knowledge. Trial designers must have an idea about the
way that patients with speciﬁc characteristics will respond to dif-
ferent treatments, or the recruitment and dropout rates. These
assumptions then form the basis of their designs for trial protocols.
Some assumptions are based on prior knowledge, others reﬂect re-
sponse to treatment expectations or anticipated phenomena such
as patient trial attendance rates, compliance with treatment, drop-
outs and adverse events, all of which can affect trial results. How-
ever, any of these assumptions may be wrong or biased due to a
lack of previous evidence or the uncertain nature of the variables.
Once a trial starts, the protocol cannot usually be changed, and
cannot be tried and retried until an efﬁcient trial has ﬁnally beenll rights reserved.
).run. If the designer’s assumptions are accurate and s/he manages
the trial strictly according to the protocol based on her/his assump-
tions, then the outcome of the trial will be reliable.
If the assumptions are wrong, the trial may yield unsatisfactory
results. If this is the case, it is always too late to start again; the
sponsor’s investment of time, money, and effort may have been
wasted and furthermore people may well have been subjected to
unnecessary inconvenience, discomfort, and health risks.
A common assumption is that there are no dropouts and many
previous methods for designing optimal clinical studies have lar-
gely overlooked patient dropout. This leads to underestimating
the number or patients who need to be recruited to achieve a desir-
able statistical power, and, consequently, additional time and fur-
ther ﬁnancing are needed to recruit more patients. It is difﬁcult to
predict the results and characteristics of clinical trial designs that
make this assumption using conventional statistical methods.
Therefore, this paper describes a simulation model for a clinical
trial that includes patients who drop out of a trial, potentially
improving the design accuracy.
With simulation, our assumptions can form an explicitly de-
ﬁned basis for a model rooted in real-world practices. From here,
we use powerful computing and statistical methods to generate
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us to test alternative models which highlight deviations from the
designer’s original assumptions. In addition, we can test alternative
protocols and discover which one will be the most robust when
studying alternative models. Each model, together with a protocol,
can be used to generate data that might have come from a real trial,
and this data can then be used to test the proposed analysis proce-
dures to ensure that the original assumptions can be tested. In this
paper we attempt to verify the hypothesis that the total cost
resulting from carrying out a clinical trial can be minimised by
using simulation models as an alternative to conventional statisti-
cal approaches.
Data and analysis results from a previous trial can provide a
strong basis for the prior knowledge necessary to simulate a new
trial and design an improved protocol, in turn, leading to stronger
assumptions.
We used the Sigma for Windows general modelling and simula-
tion package, which allows investigators to develop simulation
models according to their own needs and speciﬁcations [5]. The
computational model is available from the authors.2. Data and methods
To test and demonstrate our method, we extracted data from
the published database of a randomised clinical trial with HIV sub-
jects [6]. The resulting analysis of this data was then used to design
an improved trial.
2.1. The clinical trial
In the original trial 100 patients were recruited and 98 of these
were randomly assigned to two treatment groups: (A) protease
inhibitors and (B) nevirapine-based antiretroviral regime. The pri-
mary objective of this trial was to compare the efﬁcacies of the two
treatments in maintaining the suppression of plasma HIV-1 RNA
and permitting progressive immunologic improvement in patients.
Secondary objectives included assessing the impact of PI-sparing
regimens on metabolic proﬁles, recording other adverse events
and evaluating quality of life.
Changes in body shape were also assessed in patients with lip-
odystrophy once they began the nevirapine treatment, in compar-
ison to subjects who continued receiving PI treatment. To do this,
the trial investigator assessed the changes in the total cholesterol
level at each follow-up visit. The justiﬁcation for using the choles-
terol level as a biomarker of lipodystrophy in HIV patients was
based on their previous ﬁndings [7]. Similar ﬁndings by other
investigators were cited by the trial authors. As shown in Fig. 1,
100 patients were recruited in 12 months. Two patients were ex-
cluded from the trial and the rest were randomly assigned to either
continue with treatment A or to switch to treatment B. This meant
that 49 patients were allocated to A treatment group and 49 to the
B treatment group. There were four follow-up visits, at three
monthly intervals, to measure the cholesterol level of each patient
(see Table 1). Twenty-nine and 26 patients ﬁnished the trial under
treatments A and B, respectively. The mean cholesterol levels be-
tween the two treatments at the last visit were compared to assess
whether there were signiﬁcant differences between A and B at a le-
vel of 0.05.
In our analysis we propose two additional endpoints to measure
the effects of both treatments (see Table 2). The two endpoints are:
(1) D: mean difference in cholesterol level between the last visit
(v4) and the baseline cholesterol level before the treatment
(v0). The number of patients considered in the analysis is
the same as noted in Fig. 1 and Table 2.(2) M: mean difference between the average cholesterol level at
the last visit the patient has attended and the baseline cho-
lesterol level (M). In this case, the number of patients con-
sidered in the analysis was 47 and 48 for A and B,
respectively. This endpoint takes into account data for
patients who attend at least one visit during the trial fol-
low-up period.
In addition, we calculated the time and the cost of the trial until
its ﬁnalization. The assumed approximated values for the parame-
ters of unit cost are:
(1) Fixed cost for participating centre = €6500 (Cc).
(2) Cost per recruited patient = €60 (Crec).
(3) Cost of each evaluation visit = €30 (Cv).
(4) Monthly cost of delay due to potential sales loss = €6000
(Cd).
2.2. The conventional approach
With the two proposed endpoints, D and M, we estimated the
required sample size using formula 2. A simple adjustment to ac-
count for dropout probability can be made by dividing the sample
size by the probability of patients who complete the trial. We cal-
culated the probability of patient dropout from the trial using for-
mula 1.
PdðvÞ ¼ 1 ðnv=nv1Þ ð1Þ
This equation subtracts from 1 the quotient of the remaining num-
ber of patients n at any given visit v (v = 1, 2, 3,. . .) divided by the
number of patients n who dropped out in the previous visit. This
equation is applied to calculate the dropout probabilities for pa-
tients under both treatments, A and B. This was the equation used
in the simulation model.
For both endpoints, we assume equal variance for both treat-
ments represented by pooled standard deviation. A simple calcula-
tion of total cost of this trial can be made using formula 3, given the
rate of recruitment and duration of follow-up.
n ¼ ½2 ðza þ zbÞ2  s2=d2=½1 PdðvÞ ð2Þ
where n is the required number of patients in each group, Za is the va-
lue of Z corresponding to the risk of a (=1.96), Zb is the value of Z cor-
responding to the risk of b (=0.843), S is the standard deviation, d is
the mean difference.
Tcost ¼ Cc þ ðne þ ncÞ  Crecðne þ ncÞ  Cv þ ðtin þ tf Þ  Cd ð3Þ
where Tcost is the total cost of the trial, ne is the number of patients
in the new treatment, nc is the number of patients in the control
treatment, tin is the time to include all patients, tf is the duration
of follow-up.
2.3. The simulation model
We developed a simulation model to describe the process of
enrolling patients and their follow-up visits in clinical trials that
study continuous variables at discrete points of time, including
dropout. We divided input parameters into two categories. The
ﬁrst includes the design parameters: endpoints, number of fol-
low-up visits, number of centres and sample size. The second in-
cludes external parameters: selection rate, recruitment and
dropout rate, cost of recruitment, cost of a visit, centre cost and
opportunity costs of trial duration. The output variables are power,
total duration of the trial and total trial cost.
As shown in the ﬂow diagram in Fig. 2, the model simulates the
ﬂow of patients through the trial from the time they arrive at the
Table 1
Summary statistics of the observed data of the clinical trial
Visit A B
nA Mean SD P(v) nB Mean SD P(v)
V0 49 217 49 – 49 225 45 –
V1 47 219 45 0.041 44 212 49 0.102
V2 45 214 47 0.043 43 216 45 0.022
V3 42 217 50 0.067 40 219 40 0.069
V4 29 210 50 0.310 26 215 45 0.35
V0: baseline visit before the treatment; V1, 2, 3, 4: follow-up visits after treatment;
n: number of patients still in the trial; M: mean of cholesterol level; SD: standard
deviation; P(v): dropout probabilities.
100 patients present at one 
centre
Time = 12 months 
Cost1 = 6500 euros/centre
Cost2 = 60 euros/patient
100 possible
elegible patients 
98 randomly 
allocated
49 allocated to
nevirapine-based
antiretroviral regime 
49 allocated to Protease
Inhibitors 
2 patients 
excluded 
Follow-up at: 30 euros 
per visit and patient 
Month 3: n = 47, 
Month 6: n = 45
Month 9: n = 42
Month 12: n = 29
Follow-up at: 30 euros 
per visit and patient 
Month 3: n = 44
Month 6: n = 43
Month 9: n = 40
Month 12: n = 26
29 in analysis
20 lost to follow-up 
26 in analysis
23 lost to follow-up 
5  dropped out 
1  dropped out 
3   dropped out 
14 dropped out 
2  dropped out 
2  dropped out 
3   dropped out 
13 dropped out 
Fig. 1. Flow diagram of the original trial, used as a starting model for the simulation.
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ing to three probability distributions:Table 2
Results from the trial based on D and M endpoints
Endpoints A B Diff
ne Mean SD nc Mean SD Diff
D 29 7 50 26 10 38 3
M 48 2 36 47 9.5 30 7.(1) The probability of inclusion, which determines if the patient
is included or excluded.
(2) The probability of treatment allocation, which determines if
the patient is allocated to A treatment or to B treatment.
(3) The probability of dropout after treatment allocation at each
follow-up visit.
2.3.1. Recruitment sub-model
We assume that the monthly number of arrivals is a random
variable with a Poisson distribution and that the time between
arrivals is a random variable with an exponential distribution gi-
ven by formula 4.
ti ¼ 1c  rt  LogðRiÞ ð4Þerence: B  A
SDDiff SEDiff 95% IC lower 95% IC upper P-Value
44 11.98 26.5 20.5 0.4
5 33 6.78 20.8 5.8 0.13
Patient at the centre C, C=1, 2, 3, 4,..
Fix cost for centre: Cc
Fix cost per patient: Crec
Time = presentation rate * ln{uniform distribution (0, 1)} 
Patient included/excluded 
Prob. Included =Pin
R=RND 
Patient is randomly
allocated
R = RND 
B Treatment 
Visit 0 
dist1=N (0, s1), dist2=N (0, s2) 
Li = MeanB + dist1 + dist2
Dropout probability, Pd (v, c) = 1-e-λ(0).c
A Treatment 
Visit 0 
dist1=N (0, s1), dist2=N (0, s2) 
Li = MeanA + dist1 + dist2
Dropout probability , Pd (v, c) = 1-e-λ(0).c
Excluded 
Dropout 
Visit 1: cost = CS1
dist2=N (0, s2) 
Li = MeanB + dist1 + dist2
Dropout probability, Pd (v, c) = 1-e-λ(1).c
Dropout 
Visit 2: cost = CS2
dist2=N (0, s2) 
Li= MeanB + dist1 + dist2
Dropout probability, Pd (v, c) = 1-e-λ(2).c
Visit v: cost = CSv
dist2=N (0, s2) 
Li= MeanB + dist1 + dist2
Dropout probability, Pd (v, c) = 1-e-λ(v).c
Dropout 
Visit 1: cost = CS1
dist2=N (0, s2) 
Li = MeanA + dist1 + dist2
Dropout probability Pd (v, c) = 1-e-λ(1).c
Dropout 
Visit 2: cost = CS2
dist2=N (0, s2) 
Li = MeanA + dist1 + dist2
Dropout probability, Pd (v, c) = 1-e-λ(2).c
Visit v: cost = CSv
dist2=N (0, s2) 
Li = MeanA + dist1 + dist2
Dropout probability, Pd (v, c) = 1-e-λ(v).c
R>PrndR<=Prnd
R>Pin
R<=Pin
Dropout Dropout 
Fig. 2. Flow diagram of patients in the simulation model.
1056 I. Abbas et al. / Journal of Biomedical Informatics 41 (2008) 1053–1061The variable R denotes sampled values for i patients from a uniform
distribution that has values between 0 and 1. The parameter rt de-
notes the mean inter-arrival time of the exponential distribution
(rt = 1/N, N = number of arrivals). The parameter c denotes the num-
ber of centres participating in the trial.
The total time of the recruitment is calculated as the sum of all
inter-arrival times t for all simulated patients i from these distribu-
tions. The total cost is estimated by adding the cost by centre, the
cost per patient and the cost of delay associated with longer trial
duration.
Accordingly, the ﬁrst patient arrives at the trial at time t and is
screened to determine whether they meet the inclusion criteria
and are subsequently enrolled in or excluded from the trial. If Pin
denotes the probability of inclusion, then the patient will be in-cluded if this probability is equal or less than the probability sam-
pled from another uniform distribution R, as shown in Fig. 2.
If the patient is included, then the patient will be randomly allo-
cated to one of the two treatments (A or B) using another uniform
distribution generator between 0 and 1, fromwhich the patient has
the Prnd probability of being allocated to treatment B. The patient
then enters the follow-up sub-model as described below.
2.3.2. Follow-up sub-model
If this patient is allocated to treatment B, the corresponding
baseline value will be generated from two random variables that
follow normal distributions with 0 mean and s standard deviation
plus the mean level, that is Li = Meanv + (dist1 = N{0;s1}) +
(dist2 = N{0;s2}). At the subsequent visits of the follow-up, this
Table 3
Estimated dropout probabilities for the lower and upper case
A B
Low Mean High Low Mean High
V0 to V1 0.014 0.041 0.065 0.070 0.102 0.136
V1 to V2 0.020 0.043 0.068 0.007 0.022 0.041
V2 to V3 0.044 0.067 0.095 0.037 0.069 0.099
V3 to V4 0.254 0.310 0.370 0.296 0.35 0.412
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level) from the value generated by dist1 at the baseline visit and
the value generated by dist2 at each follow-up visit, plus the mean
value that corresponds to the actual visit. Fig. 2 illustrates how
these values are maintained throughout the simulation. Three sta-
tistical models were developed from the general model based on
different assumptions regarding the cholesterol evolution patterns
at the follow-up visit. The models are described below.
(1) Model 1:When this model is used to generate the cholesterol
value at each visit, it considers the real-world model given
by the data obtained from the trial (Table 1). This model con-
siders that the mean cholesterol level varies over visits, and
is different for the two treatments. It also considers that the
standard deviations between the two treatments are differ-
ent, and speciﬁes different standard deviations for each dis-
tribution. Therefore, the parameters, s1 and s2, were
estimated and calibrated using a method described in an
earlier publication [8].
(2) Model 2: This model differs from model 1 in that it assumes
that the study variable (cholesterol level) under treatment B
will result in a reduction of 4 mg/dl for every trial follow-up
visit. In order to maintain this assumption in the model, this
amount of the reduction was added to model 1.
(3) Model 3: This model differs from model 2 in that it assumes
that the mean baseline level of cholesterol in a new trial is
the mean level that was achieved at the last visit under A
and B of the actual trial. Moreover, we consider that this
level does not vary over the visits for treatment A, and there
is a linear reduction of 4 mg/dl under treatment B, the same
as in model 2.
After generating the cholesterol value, the model applies the
probability of a patient dropping out through another uniform dis-
tribution generator between 0 and 1. If the generated probability is
equal to or less than the dropout probability, then the patient will
continue receiving the treatment in the next visit; if not, the pa-
tient will drop out from the trial. In order to account for centre-
speciﬁc dropout probability, we converted the probability of the
trial shown in Table 1, Pd(v), into the k(v) rate given by formula
5. Then, we used the rate found to calculate the intended probabil-
ity depending on c centre, Pd(v,c), given by formula 6. This equa-
tion assumes that this dropout probability increases as the
number of centres increases according to an exponential
distribution.
kðvÞ ¼ Logð1 PðvÞÞ ð5Þ
Pdðv; cÞ ¼ 1 ekðvÞc ð6Þ
where Pd(v,c) is the dropout probability at visit v (v = 0, 1, 2,. . .) and
centre c (c = 1, 2, 3,. . .).
Assuming that the patient attends the next visit, then the value
of the outcome variable (cholesterol level) will be updated accord-
ing to the sum of the newmean level: the value generated from the
ﬁrst normal distribution Dist1 at the baseline visit and the new va-
lue generated by the second normal distribution Dist2. That is,
Li = Meanv + (dist1v = dist1v=1) + (dist2v = N{0;sv}).
This process is repeated until the patient either reaches the last
visit of the trial or the point when they drop out. In the case of pa-
tients allocated to treatment A, the model applies the same process
according to theconditions related to this treatment, as shown inFig.
2. This procedure is repeated for all patients speciﬁed in the model.
2.3.3. Estimating the results of the model
When the last simulated patient of the given sample size
reaches the last visit or drops out at an earlier visit, the modelcalculates the means and standard deviations of the selected
endpoints for each treatment. The number of dropout patients
is then calculated and recorded. The total duration and cost
are also computed applying formula 3. This single simulation
is repeated 100 times under different sequences of random
numbers starting at 12,345 random seed and up to the
12,445, producing 100 independent data sets, each of the same
sample size.
With 100 values of dropout probabilities produced by these
simulations, we estimated the upper and lower levels of dropout
probabilities from the dropout probabilities average observed in
the trial (Table 3).
One hundred means and standard deviations for each proposed
endpoint and each treatment were estimated and recorded, and
the total durations and costs were assessed for each repetition.
At this point, we used the means and standard deviations to calcu-
late the expected sampling means and standard deviations. Then,
the t-statistic was calculated for each repetition of the simulation:
dividing the differences in expected means by the expected sam-
pling distribution standard deviation. To determine the expected
statistical power, we calculated the proportion of repetitions that
reach the acceptable signiﬁcance level showing that B is better
than A. Finally, the expected duration and cost of the trial were also
estimated.
2.3.4. Number of simulations
The number of simulations is discretional. It is based on the de-
sired precision of a parameter of interest. Since we are interested in
estimating the power (p) of the trial, the number of simulations
needed can be calculated so that the standard error (SE) of the
power is minimised. Therefore, SE ðpÞ ¼ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃpð1 pÞ=rp , where r is
the number of simulations. If one wants to reduce the standard er-
ror to 0.04 for a power of 0.8, then 100 simulations would be re-
quired. With this error, the lower and upper values of 95%
conﬁdence interval of power can be calculated by IC95 ¼ p
Z1a=2  SEðpÞ ¼ 0:8 1:96 0:04. We then have a 95% certainty
that this power will be within the interval. Increasing the number
of simulations produces a narrower conﬁdence interval which
means more precision in power estimation.
2.3.5. The investigated scenarios
The simulation model analysed the impact of each model and
dropout assumptions on power, total duration and cost of a new
trial. For each model, we created three scenarios, and for each sce-
nario we ran different simulations using different parameters. Each
simulation involved generating 100 independent simulated data
sets for a given parameter combination.
The three scenarios were:
(1) Scenario 1. There are no dropouts from the trial: the trial is
simulated at 1, 2, 3, 4, and 5 centres when using model 1,
and is simulated at only one centre when using models 2
and 3. The recruitment rate and cost parameters used were
those assumed by the trial. There are 100 replications for dif-
ferent sample sizes.
Table 4
Conventional and simulation results of power, total duration (months) and cost (€)
N = 600 Centres D-P M-P TD TCost
invF2 1 0.09 0.75 84.0 619
Model 1-Scenario 2 1 0.09 0.85 84.5 606
2 0.01 0.82 48.5 392
3 0.07 0.88 36.4 319
4 0.04 0.80 30.7 291
5 0.03 0.86 27.4 275
Model 1-Scenario 3 1 0.25 0.85 84.5 606
2 0.13 0.82 48.5 392
3 0.29 0.88 36.4 319
4 0.22 0.80 30.7 291
5 0.26 0.86 27.4 275
invF2, the inverted formula 2 for power calculation; D-P, expected power consid-
ering D as the endpoint of the trial; M-P, expected power considering M as the
endpoint of the trial; TD, expected total duration of the trial; TCost, expected total
cost of the trial.
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in that it considers dropout rates before and after patient
allocation to one or other treatment. The dropout rate
before randomisation is the inverse of inclusion probabil-
ity, which is set to 0.98. After randomisation, the low,
mean, and high dropout probabilities shown in Table 4
were considered depending on follow-up visits. We used
a pre-protocol method (PP) to analyse the data resulting
from the simulations. This method considers only patients
who were randomly assigned to A and B treatment and
ﬁnished the trial.
(3) Scenario 3. This scenario replicates scenario 2, but uses the
intention to treat method (ITT) for data analysis [9]. This
method means that all randomised patients are considered
who were evaluated for at least one visit after randomisa-
tion. If the patient drops out before the end of the trial, the
study variable level (in this case, cholesterol level) at the last
visit attended is assumed to be that of the last visit of the
trial.3. Results
3.1. The conventional approach
Table 1 illustrates the mean and standard deviation cholesterol
level measured at each trial visit. It also gives the number of pa-
tients that were randomised and the number still in the trial at
each visit. The number of patients initially included in the original
trial (98) was insufﬁcient to achieve a statistically signiﬁcant dif-
ference between the treatments at a level of 0.05.
The mean cholesterol levels between the two treatments at
the last visit were compared, but this comparison is not relevant
since the cholesterol level distribution parameters at the base-
line visit are not equal (see Table 1). Therefore, the mean choles-
terol level at the last visit was compared with the baseline level
for each treatment on a separate basis. Again, there were no sig-
niﬁcant statistical differences in cholesterol level reductions.
Consequently, the trial concludes that the hypothesis of switch-
ing to B treatment is better than continuing with A treatment is
rejected.
Comparing the two treatment effects based on the two pro-
posed endpoints, D and M, the results in Table 2 show that the trial
still does not reach the statistical signiﬁcance target level
(P > 0.05). In addition, the conﬁdence interval of every mean differ-
ence includes zero. Thus, all the analyses indicate that there is no
signiﬁcant difference between the effects of the two treatments.This meant a delay of 24 months and an opportunity cost of
about €298,000. The negative results of the trial could have been
due to several possible reasons, such as too small a sample size,
too short a duration, or simply that the treatment did not work.
A review of general causes of negative results can be found in [10].
According to the sample size determined by using formula (2),
the two proposed endpoints could have reached a statistically sig-
niﬁcant difference between treatments with the desired power,
but only with additional information. If the designer plans a new
trial considering D as the endpoint of the trial, a sample size of
6887 patients is needed to reach a level of 0.05 statistical signiﬁ-
cance with a power of 0.8. If we assume a dropout probability of
43%, as in the original trial, this requires a sample size of 12,044 pa-
tients. Given the observed rate of recruitment, approximately 130
years and more than €6,000,000 are needed to enrol the number of
patients required in one centre. Therefore, the trial would not be
feasible.
However if the designer considers M as the endpoint of the trial,
a sample size of only 613 patients is needed to show that the new
treatment is better, meaning that a period of 84 months is needed
for enrolment and follow-up. In this case, the trial would cost
€587,000. If we consider that 9% of patients will dropout before
the ﬁrst follow-up visit, as shown in Table 2, then this requires a
sample size of 674 patients and a corresponding period of 92.9
months for the trial. In this case, the total cost would be
€685,220. Once again, the trial may not be feasible due to time
restrictions.
3.2. Modelling approach
Whenever one develops a model, the ﬁrst question to ask is
whether its results are internally validated or not. Table-S1 gives
the statistical results of cholesterol level for model 1, assuming
no dropout rates and given different sample sizes. As expected,
the sampling standard deviation decreases as the number of pa-
tients increases both for D and M endpoints. Comparing them with
those of the clinical trial, we found that the model performs well
replicating the results of the trial with an acceptable error level.
The relative errors of simulated and observed parameter standard
deviations are below 10%. The standardised differences between
observed and simulated means are also below 10%. We also quan-
tiﬁed the coverage assessment of the model using the 95% conﬁ-
dence interval. We estimate the proportion of times that the 100
simulated conﬁdence intervals contain the parameter of interest,
which is the difference between the two treatments. We found that
98% and 99% of simulated intervals contained this parameter for
the D and M endpoints, respectively. The two standard deviations,
s1 and s2 were estimated at 38 and 34 for treatment A, and 36 and
27 for treatment B. Therefore, the results of the model are valid and
the model can then be used to represent an experiment.
Fig. 3 illustrates the expected power of model 1 under scenario
1 and 2. In the case of endpoint D, we found that the power does
not change when increasing the sample size (lower lines). How-
ever, with endpoint M, it increases as sample size increases. When
dropouts are considered under scenario 2, higher power was
shown in all cases of dropout rates. Fig. 4 illustrates the expected
duration (TD, in months) and cost (€) depending on sample sizes
and centres.
Figs. 5–7, show the expected power of model 1 under scenario
3, for low, mean and high dropout rates, respectively. For both end-
points, these rates verify that the power increases as sample size
increases for any number of centres. Moreover, the expected power
increases as the dropout rate increases. As expected, the total cost
is reduced by increasing the number of centres and dropout. This is
because dropout patients from the trial did not attend all the re-
quired visits. The expected duration decreases as the number of
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dropout rates.centres increases, irrespective of whether dropout rates are high or
low. This is because (1) all patients who participated in the trial are
screened; (2) screened patients are enrolled immediately; and (3)
the follow-up visits are ﬁxed.
Using model 2, endpoint M continues to be more efﬁcient than
endpoint D (see Figure-S1 and Figure-S2), however, D is more efﬁ-
cient than M using model 3 (see Figure-S3 and Figure-S4). The re-
sults of these two models show that the expected power decreases
as the dropout increases, and the total durations and costs were re-
duced for all dropout assumptions for both models and scenarios.
However, the reduction of power must be compensated for by add-
ing the information for new patients, which means investing more
time and money.
Furthermore, Table-S2 illustrates that the relative difference in
the number of allocated patients between the two treatments
depending on the centre would result only in a minor deviation.
1060 I. Abbas et al. / Journal of Biomedical Informatics 41 (2008) 1053–1061These results ensure that the simulation model achieves a good
balance which results in a high degree of precision regarding
power estimation.
3.3. Comparing the conventional vs. the modelling approach
Assuming M to be the endpoint of the trial, and considering the
mean probabilities of dropout, according to the conventional ap-
proach 674 patients are needed to attain a power of 0.8 for a signif-
icant level of 0.05 to conclude that there is a signiﬁcant difference
between the two treatments. The expected cost resulting form the
trial would be €685,000.
However, if we apply the modelling approach we can see that
600 patients would be enough to attain the same objective at a
lower cost. Carrying out the trial at one centre with 600 patients,
we would obtain the expected results illustrated in Table 4. The
conventional approach represented by the inverted formula (2)
(invF2) estimates that the trial would achieve a power of 0.75 at
a cost of €619,000 if M is used to measure the efﬁcacy of the trial.
However, the modelling approach estimates that a power of 0.85
would be achieved at a lower cost (€606,000). Moreover, assuming
that the two approaches attain the target signiﬁcance level of dif-
ference at the same power, as shown in Table 4 for D endpoint with
scenario 2, the cost is minimised by simulation because it takes
into account the patients that dropped out at different moments
during follow-up, as would happen in real clinical trials.
While the conventional approach is not able to consider multi-
centre trials, the simulation model provides results that are even
more efﬁcient, as shown in Table 4. The power is maintained high
enough with the M endpoint, it is increased with the D endpoint
according to intention to treat, and duration and cost are
minimised.4. Discussion and conclusions
A general simulation model was developed using data and re-
sults of a clinical trial that had already been run to show how
new clinical trials could be designed better. Our assumptions form
the basis of a model of the real world, for which we used powerful
computing and statistical methods to generate data as if they had
come from real patients.
The trial, as originally designed, showed no signiﬁcant differ-
ences between the two treatments; consequently, the time and
money invested in it have been lost, as the trial will not lead to a
better treatment for the patients.
Trial data and the assumed two endpoints enable us to plan a
new trial to test the results with additional information. We esti-
mate the required sample size, the time and cost using the con-
ventional approach based on the results of the trial and the
assumptions of the designer. This approach does not consider
cost factors that determine the efﬁciency of the trial, and fur-
thermore, many assumptions have to be made. Formula (2) as-
sumes constant changes and equal standard deviations of the
outcome of the two compared treatments. Nevertheless, when
the variances are different, the assumption that they are equal
leads to wrong estimates of sample size or of the power of the
trial. The correlations between measurements at different visits
are not taken into account, and thus these measurements are
treated as independent. This, again, leads to a misestimating of
the real effects of the trial and thus of the power of the trial
[11]. Moreover, if the designer of the trial wants to account for
centre-speciﬁc dropout probabilities, the conventional approach
to power estimation cannot be applied. Formulas for approxi-
mating the results considering these characteristics of clinical
trial design are either not available or difﬁcult to apply.In these situations, computer simulation is the only alternative.
It has been applied to different situations to determine sample size
for clinical trials which investigate treatment differences in re-
peated measurements when a continuous variable is evaluated
over ﬁxed periods. Ahu et al. [12] applied a model assuming that
changes in the mean response variable are constant over time. Pa-
tient dropout probability is independent and uniformly distributed
over a given period. Mayer-Hamblett and Kronmal [13] used sim-
ulation to study a continuous variable when response variable
changes are not constant over given periods. They investigated
optimal endpoints that minimise sample size while still detecting
signiﬁcant treatment differences. However, these papers did not
consider the dropout probabilities nor the effect of multi-centre
trials on power estimation or cost.
The simulation results showed that whether dropout rates are
assumed or not, deﬁning the endpoint in terms of the mean differ-
ence between the average of the four visits and the baseline cho-
lesterol levels is more efﬁcient than using the mean difference in
cholesterol levels between the last visit and the baseline choles-
terol. This is likely to be the case whenever cholesterol level
changes are not constant over time. However, when the changes
are constant, the results showed that the mean difference between
the last and the baseline cholesterol level is more efﬁcient. This is
similar to the ﬁndings of a previous study [13]. We can be therefore
concluded that, if an efﬁcient endpoint is used to measure the dif-
ference between the two treatments, power, duration and costs of
the trial will be optimised.
Conventional approaches to clinical trial design, such as formula
(2), usually predict that the power of the trial will be reduced when
dropout rates are considered. However, we have shown that this
prediction is not always true. If changes in mean cholesterol were
variable over a given period, we found that the power increased
when considering dropout patients. It is clear that when formula
(2) is used to adjust sample size, it considers only overall probabil-
ity of dropout patients and cannot take into consideration time-
dependent probabilities, such as those shown in Table 3. This will
overestimate power and sample size, and, consequently, duration
and cost. Moreover, the total cost by itself is overestimated be-
cause the conventional approach for estimating sample size or
power ignores the cost of patients who drop out from the trial be-
fore the last or follow-up visits. As we have shown, the simulation
model provides a more accurate adjustment of power for a smaller
sample size, and the total cost is also minimised for any given
dropout probability.
Furthermore, one of the problems of modelling multi-centre tri-
als, especially in small trials, is the difﬁculty of ensuring a balanced
treatment-patient allocation. The most common approach adopted
to ensure an optimal balance between groups in small trials, is to
use allocation by minimisation [14]. This approach consists of allo-
cating patients to treatments groups according to a set of charac-
teristics. The allocation is not totally random in practice since it
is based on random and deterministic components depending on
the characteristics of patients who have been allocated to treat-
ments [15].
In this study, we used a simple randomization approach to allo-
cate patients to the two treatments, and we applied the method of
repetitions to estimate the results. Assuming a multi-centre trial,
we found that this method achieved a high balance between cen-
tres. Patients are allocated to the two treatments with minor vari-
ations, depending on the centre. This method is intuitive and is
easy to apply, particularly when there are many factors in large
or small trials. In addition, the process is totally random and it
can be extended to account for more variables such as gender
and patient’s age. However, we are constrained by computing time
and cost because many replications are needed to reduce variabil-
ity of the results. One can use supercomputing to reduce the cost of
I. Abbas et al. / Journal of Biomedical Informatics 41 (2008) 1053–1061 1061variability reduction, and consequently, to reduce the uncertainty
of multi-centres clinical trial results.
We constructed a general model in such a way that parameters
can easily be modiﬁed in order to analyse alternative continuous
variables and/or scenarios and assumptions. The cholesterol vari-
able used in the model can be changed to other variables, such
as CD4 and viral load. Therefore, mean, variance and correlation
structures can be speciﬁed according to the new variable. Recruit-
ment rate, probability of inclusion, dropout rates and cost can be
modiﬁed to produce new analyses. The model can simulate the
trial for different numbers of follow-up visits in order to determine
the optimal number of repeated measures, subject to power, dura-
tion or cost constraints. This will enable the designer to estimate
the number of visits needed for acceptable statistical power. Thus,
if the designer modiﬁes the parameters, the model will generate
new results. The impact of these modiﬁcations on the results can
be quantiﬁed, and therefore the combination of parameters that
provides optimal results can be anticipated before the real-world
trial is carried out. We have deliberately omitted some variables
that would be included in a thorough study, such as viral load,
CD4 counts and clinical outcomes, to simplify the description of
our method.
In conclusion, simulations can be applied easily to real situa-
tions of clinical trials to test the performance of investigators’
assumptions. Simulations can also be used to reveal the optimal
design parameters for a clinical trial before it is put into operation
in the real world. We have shown how simulation avoids the lim-
itations of the conventional approach to clinical trial design by pro-
viding a more accurate determination of power, and minimising
the total cost of clinical trials.
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